News
Public · Published
SYNGENE: Q2 revenue recovered QoQ, but forex losses and lower YoY earnings weighed on margins
Syngene's Q2 FY27 revenue rose 13% quarter on quarter but fell 9% year on year, while profit after tax before exceptional items was Rs 38 Cr. Operating EBITDA margin was 18%, and losses on foreign exchange hedges weighed on results.
Published:
Updated:
What happened
Syngene's Q2 FY27 revenue rose 13% quarter on quarter but fell 9% year on year, while profit after tax before exceptional items was Rs 38 Cr. Operating EBITDA margin was 18%, and losses on foreign exchange hedges weighed on results.
Confirmed
Global impact / market context
A 9% yearly revenue drop plus forex hedge losses, which are costs from contracts meant to offset currency swings, squeezed profit. Cost initiatives and new biologics contracts, meaning work on biological drugs, are the stated supports for future execution.
Analyst inference
The quarter shows a recovery from the prior quarter but still weaker earnings than a year earlier. Investors weighing Syngene face a company where revenue momentum is improving sequentially while hedging costs and yearly comparisons pressure margins.
Analyst inference
What to watch
- Cost initiatives are cited as supporting future execution, so watch whether these efforts show up in operating EBITDA margin, which was 18% in Q2 FY27. Confirmed
- Track new biologics contracts, which are agreements to make biological drugs, for signs they add revenue and help offset the 9% year-on-year revenue decline. Proposed
- Watch forex hedge losses, which are costs from currency-protection contracts, because they weighed on results and could keep pressuring profit if they persist. Analyst inference
Evidence
- Original source link unavailable